Immuneering Corporation (IMRX)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
Immuneering (IMRX) Upgraded to Buy: Here's What You Should Know
Immuneering (IMRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
IMRX Begins Dosing in Phase III Pancreatic Cancer Study, Stock Up
Immuneering stock rises after dosing the first patient in a pivotal phase III study of atebimetinib plus mGnP for first-line metastatic pancreatic cancer.
Immuneering Corporation: Updates Inbound At The End Of The Month
Immuneering Corporation (IMRX) presents promising early data in frontline metastatic pancreatic cancer with its MEK inhibitor atebimetinib, benchmarking favorably against Revolution Medicines. IMRX's 12-month overall survival rate of 64% in a small phase 2a trial compares well to historical controls and competitive agents, but caution is warranted due to trial size. The company maintains over $200 million in liquidity, supporting a cash runway into 2029, though future trial costs may shorten this horizon.
Immuneering Corporation Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| RF Rekah Franca Catalyst Funds Management Pty Ltd. | 12,800 | $67,456 | $65,792 | -$1,664 | -2.47% |
| RO Regan O'Neill Burkehill Global Management LP | 300,000 | $2.1M | $1.55M | -$553,500 | -26.36% |
 Li Peng China Universal Asset Management Co. Ltd. | 11,458 | $75,786.76 | $59,123.28 | -$16,663.48 | -21.99% |
| DP Drew Phillips Fortitude Family Office LLC | 105 | $553 | $525 | -$28 | -5.06% |
 Joshua Stipcich Tidemark, LLC | 10,000 | $24,900.1 | $49,250 | $24,349.9 | 97.79% |
Immuneering Corporation Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Geulah Livshits Chardan Capital | 3,080.75 | $14,664.39 | $15,896.69 | $1,232.3 | 8.4% |
Immuneering Corporation (IMRX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Immuneering Corporation ever had a stock split?
Immuneering Corporation Profile
| Biotechnology Industry | Healthcare Sector | Benjamin J. Zeskind CEO | NASDAQ (NMS) Exchange | 45254E107 CUSIP |
| US Country | 37 Employees | - Last Dividend | - Last Split | 30 Jul 2021 IPO Date |
Overview
Immuneering Corporation is a clinical-stage oncology company dedicated to the development of innovative medicines targeting a broad spectrum of cancer patients. Established in 2008 and headquartered in Cambridge, Massachusetts, the company focuses on creating solutions to address the unmet needs of patients suffering from various types of cancer. With a commitment to advancing cancer treatment, Immuneering Corporation leverages its expertise to develop therapies that aim to improve outcomes for patients facing this challenging disease.
Products and Services
IMM-1-104: This leading product candidate from Immuneering Corporation represents a significant advancement in cancer therapy. As a dual-MEK inhibitor, IMM-1-104 is currently undergoing a Phase 1/2a clinical trial. The drug is designed to treat patients with several types of cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer. Specifically targeting mutations of RAS and/or RAF, IMM-1-104 aims to offer a new hope for patients whose cancers are driven by these genetic alterations.
IMM-6-415: Another promising addition to the company’s portfolio, IMM-6-415, is in the stage of an Investigational New Drug (IND) application. Focused on treating solid tumors, IMM-6-415 embodies the innovative approach of Immuneering Corporation to cancer treatment. By developing drugs like IMM-6-415, the company strives to expand the arsenal of therapeutic options available to patients dealing with complex, challenging tumors.
